A federal judge in Delaware tossed out a lawsuit by Roche company Genentech accusing Novartis’ Sandoz division of patent infringement. In this case, the patent was related to Genentech’s Esbriet (pirfenidone), which is used to treat idiopathic pulmonary fibrosis.

A federal judge on March 21 said Apple Inc. must face a Silicon Valley company’s claims it illegally monopolized the U.S. market for heart rate monitoring apps for the Apple Watch.

A federal judge on February 16 dismissed a proposed class action lawsuit by consumers who accused Pfizer Inc. of failing to disclose the presence of cancer-causing agents in Chantix before recalling the anti-smoking drug.

The three largest U.S. drug distributors and drugmaker Johnson & Johnson agreed to pay $590 million to resolve claims by Native American tribes that the companies fueled an opioid epidemic in their communities, according to court filings.

A federal judge on Feb. 1 extended a legal shield protecting the Sackler family owners of Purdue Pharma from lawsuits to Feb. 17, as they try to reach a deal with several states to settle sprawling litigation stemming from the U.S. opioid crisis.

The U.S. Food and Drug Administration said on Sept. 9 the regulatory agency needs more time to decide whether e-cigarette maker Juul Labs Inc. and other major manufacturers can sell their products in the United States.

A U.S. appeals court on Aug. 26 threw out a $1.2 billion ruling against Gilead Sciences Inc., finding a patent on a cancer therapy the company was accused of infringing was invalid, in a blow to rival Bristol Myers Squibb Co.

Less than two months after life sciences giant Bayer acquired N.C.-based gene therapy company AskBio, the healthcare company launched a cell and gene therapy platform within its pharmaceutical division.

Catalyst Pharmaceuticals filed new patent infringement lawsuits against Jacobus Pharmaceuticals and PANTHERx Rare LLC over a treatment for the rare autoimmune disease Lambert-Eaton Myasthenic Syndrome (LEMS).

A federal judge dismissed Catalyst Pharmaceuticals’ lawsuit against the U.S. Food and Drug Administration regarding the approval of a rival drug for a rare autoimmune disease from New Jersey-based Jacobus Pharmaceutical.